chevron_leftBack
As of 24 April 2025, Polarean Imaging plc has a market cap of $16.46M USD, ranking #30857 globally and #698 in the United Kingdom. It ranks #3096 in the Healthcare sector, and #387 in the Medical Devices industry.
Key Stats
Market Cap
$16.46MUSD
12.37M GBP
Enterprise Value
$597.39KUSD
449.15K GBP
Revenue (TTM)
$1.97MUSD
1.48M GBP
EBITDA (TTM)
-$8.6MUSD
-6.47M GBP
Net Income (TTM)
-$8.99MUSD
-6.76M GBP
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Medical Devices
CEO
Christopher Von Jako
open_in_new
Employees
29
Founded
2016
Website
polarean.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -2.1% | 0.5% | -17% | -13% | -24% | -70% |
Upcoming Earnings
Earnings Date
Thu, May 22
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
POLX
Polarean Imaging PLC Ordinary Shares
ISIN: GB00BF3DT583
Shares Out.:
Shares Outstanding:
1.207B1
Shares Float:
600.319M2
|
1 GBX | |
|
PLLWF
Polarean Imaging PLC Ordinary Shares
ISIN: GB00BF3DT583
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.0110 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Polarean Imaging plc
Polarean Imaging plc operates as a drug-device manufacturer and service provider for noble gas polariser devices in Canada, the United Kingdom, and the United States. It engages in the research, development, and commercialization of novel imaging solutions with a non-invasive and radiation-free functional imaging platform. The company also offers XENOVIEW, a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older; and measurement station, chest coil, and dose delivery inhalation bags. Polarean Imaging plc was incorporated in 2016 and is based in London, the United Kingdom.
